Edwards Lifesciences Corp. remains interested in developing transcatheter mitral valve repair technology to build on its success in the transcatheter aortic valve space, the company says.
In addition to ongoing internal development efforts, acquisitions remain a possibility in the transcatheter mitral valve space, CEO Michael Mussallem suggested June 20 at the Wilson Sonsini Goodrich & Rosati...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?